An ever-expanding number of ACC tumors are being sequenced, with data suggesting genomic alterations in several pathways (i.e., MYB transcriptional activator family, EGFR/KRAS pathway, chromatin remodeling, tyrosine kinase signaling, and DNA damage/checkpoint signaling) as potential areas that may be amenable to directed therapeutic action [12,13,48,90]. This evidence concerns the gene EGFR and adrenal cortex carcinoma.